LUN and HLUNA Related Headlines
Go Back- Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck presents Phase 1b data for Parkinson's drug at conference
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
- Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
- Lundbeck to present Phase 3 trial data for rare brain disease treatment
- Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
- Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
LUN and HLUNA Related Press Releases
Go Back- Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
- Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
- Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026
- Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
- Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
- Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
